0000000000367608

AUTHOR

Ageno Walter

showing 4 related works from this author

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multi…

2020

Abstract Aims To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. Methods and results We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of (i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities. Up to two nights of hospital stay were permitted. Rivaroxaban was given at the approved dose for PE for ≥3 months. The primary outcome was sympto…

Malehome treatmentpulmonary embolismrisk stratification030204 cardiovascular system & hematology0302 clinical medicineRivaroxabanRecurrenceRisk FactorsOutpatientsMedicineProspective StudiesRight ventricular dysfunctionEarly dischargeAged 80 and overeducation.field_of_studyHome treatmentriskinarviointiMiddle AgedEUROPEAN-SOCIETYPatient DischargeINPATIENT TREATMENT3. Good healthPulmonary embolismTreatment OutcomeHOSPITALIZATIONAmbulatoryright ventricular dysfunctionFemaleCardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyAdolescentmanagement trialpotilaan kotiuttaminenkotihoitoPopulationDrug Administration Schedule03 medical and health sciencesYoung AdultInternal medicineMANAGEMENTkliiniset kokeetHumansseurantaddc:610Home treatment; Management trial; Pulmonary embolism; Right ventricular dysfunction; Risk stratification; RivaroxabaneducationRisk stratificationAgedRivaroxabanbusiness.industryManagement trial030229 sport sciences3126 Surgery anesthesiology intensive care radiologymedicine.diseaseInterim analysisOUTPATIENT TREATMENTConfidence intervalhyytymisenestohoitoClinical trialTHROMBOSIS3121 General medicine internal medicine and other clinical medicinelääkehoitosydän- ja verisuonitauditveritulppabusinessPulmonary EmbolismFactor Xa InhibitorsEuropean heart journal
researchProduct

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ER…

2020

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

ORAL ANTICOAGULANT-THERAPYdiagnosis[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematologyEmbolectomyGuidelineRECURRENT VENOUS THROMBOEMBOLISM0302 clinical medicinePregnancyDaily practiceDiagnosisPulmonary medicineVenous thrombosisPulmonary MedicineThrombolytic TherapyDEEP-VEIN THROMBOSISDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUShealth care economics and organizationsRisk assessmentddc:616RIGHT-VENTRICULAR DYSFUNCTIONDisease ManagementShockMOLECULAR-WEIGHT HEPARINThrombolysishumanities3. Good healthPulmonary embolismEuropeAnticoagulation; Biomarkers; Diagnosis; Dyspnoea; Echocardiography; Embolectomy; Guidelines; Heart failure; Pregnancy; Pulmonary embolism; Right ventricle; Risk assessment; Shock; Thrombolysis; Treatment; Venous thromboembolism; Venous thrombosismedicine.veinEchocardiographyAcute DiseaseRight ventricleMedical emergencyCardiology and Cardiovascular MedicineRisk assessmentguidelines; pulmonary embolism; venous thrombosis; shock dyspnoea; heart failure: right ventricle: diagnosis; risk assessment: echocardiography; biomarkers; treatment; anticoagulation; thrombolysis; pregnancy; venous thromboembolism; embolectomyDiagnosiVenous thromboembolismthrombolysiseducationCardiologyMEDLINEThrombolysiHeart failure610 Medicine & healthGuidelinesInferior vena cava2705 Cardiology and Cardiovascular MedicineEXTRACORPOREAL MEMBRANE-OXYGENATION03 medical and health sciencesAnticoagulationMedicalDyspnoeamedicineHumansRIGHT HEART THROMBIVENTILATION-PERFUSION SCINTIGRAPHYshock dyspnoeaHealth professionalsbusiness.industryINFERIOR VENA-CAVA10031 Clinic for Angiologyheart failure: right ventricle: diagnosisPulmonary embolismAnticoagulantsbiomarkersrisk assessment: echocardiography030229 sport sciencesBiomarkermedicine.diseaseTreatmentINHALED NITRIC-OXIDESocietiesbusinessBiomarkers
researchProduct

Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normali…

2012

Subtherapeutic international normalized ratio (INR) is frequently encountered in clinical practice, and patients with high-risk atrial fibrillation (AF) and with mechanical heart valve (MHV) with inadequate anticoagulation may be exposed to an increased risk of thromboembolic events (TE). However, there are no prospective data evaluating this risk. Consecutive patients with a history of stable anticoagulation, but with a subtherapeutic INR, were prospectively included. Data on use and dose of low-molecular weight heparin (LMWH) bridging therapy were collected. The incidence of objectively confirmed TE and of major bleeding events within 90 days after the index INR was assessed. Five hundred…

MaleRiskmedicine.medical_specialtyPopulationvenous thromboembolismHemorrhageComorbidityThrombophiliaFollow-Up StudiePostoperative ComplicationsInternal medicineThromboembolismAtrial FibrillationmedicineHumansThrombophiliaProspective StudiesInternational Normalized RatioeducationProspective cohort studyAgedAged 80 and overHeart Valve Prosthesis Implantationeducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceMedicine (all)WarfarinAnticoagulantAnticoagulantsAtrial fibrillationHematologyHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseConfidence intervalSurgeryProspective StudieHeart Valve ProsthesiHeart Valve ProsthesisFemalePostoperative ComplicationWarfarinbusinessCohort studymedicine.drugFollow-Up StudiesHuman
researchProduct

Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation

2015

Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 yea…

RegistrieMaleCross-sectional studyMyocardial InfarctionLongitudinal StudieLeft ventricular hypertrophyCohort Studiesnon-valvular atrial fibrillationAtrial Fibrillation80 and overPrevalenceechocardiographyMyocardial infarctionLongitudinal StudiesProspective StudiesRegistriesProspective cohort studyUltrasonographyAged 80 and overeducation.field_of_studyMedicine (all)Atrial fibrillationDiabetes MellituMiddle AgedLeft Ventricularleft ventricular hypertrophyItalyHypertensionCardiologyAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular Medicine; Medicine (all)Hypertrophy Left VentricularFemaleCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyLogistic ModelPopulationConcentric hypertrophySocio-culturalenon-valvular atrial fibrillation left ventricular hypertrophy echocardiography cardiovascular diseasesPeripheral Arterial DiseaseAge DistributionInternal medicinemedicineDiabetes MellitusHumansAnkle Brachial Indexcardiovascular diseaseseducationAgedCross-Sectional Studiebusiness.industryAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular MedicineOdds ratioHypertrophymedicine.diseasecardiovascular diseasesProspective StudieCross-Sectional StudiesLogistic ModelsCohort StudiebusinessAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries
researchProduct